Glenmark Launches Apremilast

InnoHEALTH Magazine — Thu, 05 Apr 2018 09:03:25 +0000

Glenmark Launches ‘Apremilast’ – A Revolutionary Advanced Oral Treatment for Psoriasis

Globally, about 3% of the world population has some form of psoriasis. Another study reveals that the prevalence of psoriasis in countries ranges between 0.09% and 11.43%, making psoriasis as one of the serious issues.

Glenmark Pharmaceuticals Limited, a research-led global integrated pharmaceutical company which has been in the field of dermatology for more than four decades, now has announced the launch of Apremilast under the brand name ‘APREZO’, the first advanced Oral Systemic treatment for psoriasis in India which is also DCGI approved. Apremilast is a phosphodiesterase4 (PDE4) inhibitor which is indicated for the treatment of moderate to severe psoriasis. The launch of Apremilast will revolutionize the treatment of psoriasis impacting close to 33 million Indians suffering from the condition.

Apremilast is an advanced oral treatment for psoriasis which addresses the limitations of the current available therapies in India. It acts in a targeted manner at an early stage of the disease progression and is also an immunomodulator which treats the condition at an intracellular level whereas the other available drugs in the country are immunosuppressant. It is an oral therapy which can be self-administered unlike some of the currently available injectable therapies which have to be administered by paramedics. Further, Apremilast is a safer drug having no effects on other organs like the liver and kidney and does not require routine laboratory diagnostic tests like CBC, liver and Kidney test or TB screening as required in the case of other therapies used currently.

India has now become one of the largest patient pools in the world and is estimated to have around 33 million psoriasis patients. As per a study on psoriasis in India, based on data collected across various medical colleges located in Lucknow, Dibrugarh, Kolkata, Patna, Darbhanga, New Delhi and Amritsar. It was found that the incidence of psoriasis among total skin patients ranged between 0.44 and 2.2%. It was also found that the ratio of male to female (2.46:1) was very high and the highest incidence was noted in the age group of 20-39 years.

Want to write for InnoHEALTH? send us your article at magazine@innovatiocuris.com

Read all the issues of InnoHEALTH magazine:
InnoHEALTH Volume 1 Issue 1 (July to September 2016) – https://goo.gl/iWAwN2
InnoHEALTH Volume 1 Issue 2 (October to December 2016) – https://goo.gl/4GGMJz
InnoHEALTH Volume 2 Issue 1 (January to March 2017) – https://goo.gl/DEyKnw
InnoHEALTH Volume 2 Issue 2 (April to June 2017) – https://goo.gl/Nv3eev
InnoHEALTH Volume 2 Issue 3 (July to September 2017) – https://goo.gl/MCVjd6
InnoHEALTH Volume 2 Issue 4 (October to December 2017) – http://amzn.to/2B2UMLw
InnoHEALTH Volume 3 Issue 1 (January to March 2018) – https://goo.gl/fksdQx

Connect with InnovatioCuris on:
Facebook: https://www.facebook.com/innovatiocuris
Twitter: https://twitter.com/innovatiocuris
LinkedIn: https://www.linkedin.com/groups/7043791
Stay updated about IC, visit: www.innovatiocuris.com

The post Glenmark Launches Apremilast appeared first on InnoHEALTH magazine.

PRACTO INTRODUCED PRACTO RAY TAB

InnoHEALTH Magazine — Mon, 24 Jul 2017 07:39:49 +0000

[vc_single_image image=”944″ img_size=”146×200″ onclick=”link_image” qode_css_animation=””]

PRACTO RAY TAB Introduces Digital Consent Forms for the first time in India
Dr. Avantika Batish is working as Director Strategy and Healthcare at International Health Emergency Learning and Preparedness. Also, guest faculty for MBA (HR) and MBA Healthcare Management at various B-Schools and is a soft skills trainer.

[vc_empty_space]

For the very first time consent forms have been given the digital makeover. Practo, the leading digital healthcare platform has announced the integration of consent forms into the Practo Ray Tab for the first time. Available across general, dental, dermatology and gynaecology practices; the integration is aimed to further digitise practice management and ensure that patients sign the form before they undergo any treatment or surgery.

Clinics can customise the form as per their needs and create different consent forms based on different treatments.

In June, 2014 Practo Tab was built to serve as a seamless companion for Practo Ray- the widely- used practice management and appointment scheduling software for doctors and clinics. Practo Tab is an all-in-one device empowering practice management and enhancing patient relationship management.

The digital consent form will further strengthen the existing portfolio of services that are being offered on Practo Tab including patient registration, feedback, schedule management, billing etc. and help doctors manage their clinic from anywhere as all information is available on the cloud and accessible offline as well as online.

The digital consent forms available on Practo Tab are legally compliant and uses electronic signatures as per Sec 2 (ta) of Information Technology Act 2000. With the integration of consent form on Practo Tab, we will be able to provide better tools to doctors and significantly improve patient’s healthcare experience.

[vc_empty_space]

Want to write for InnoHEALTH? send us your article at magazine@innovatiocuris.com

[vc_separator type=”normal”]

Connect with InnovatioCuris on:
Facebook: https://www.facebook.com/innovatiocuris
Twitter: https://twitter.com/innovatiocuris
Linkedin: https://www.linkedin.com/groups/7043791
Stay update about IC by visiting: www.innovatiocuris.com

Connect with InnoHEALTH 2017 on:
Facebook: https://www.facebook.com/innohealth2017
Twitter: https://twitter.com/innhealth2017
Linkedin: https://www.linkedin.com/groups/7043791
Stay update about the conference by visiting: www.innohealth.in

The post PRACTO INTRODUCED PRACTO RAY TAB appeared first on InnoHEALTH magazine.

Dermatology Archives - InnoHEALTH magazine

Glenmark Launches Apremilast

PRACTO INTRODUCED PRACTO RAY TAB